Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Oxaliplatin in Stage II and III Colorectal Cancer
NCT01196260Phase 3Unknown
- Sponsor
- State Key Laboratory of Cancer Biology
- Start
- Jan 2004
- Primary completion
- Dec 2020
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of capecitabine and oxaliplatin in colorectal cancer (CRC), sponsored by State Key Laboratory of Cancer Biology. Primary endpoints: Objective Response Rate at 7 years, Relapse Rate at 7 years and 1 more. Status: unknown.
02
Drugs
capecitabineoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01196260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01196260.